The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris | Zendy

Nathan P. Wiederhold | Zendy; Shawn R. Lockhart | Zendy; Laura K. Najvar | Zendy; Elizabeth L. Berkow | Zendy; Rosie Jaramillo | Zendy; Marcos Olivo | Zendy; Edward P. Garvey | Zendy; Christopher M. Yates | Zendy; Robert J. Schotzinger | Zendy; Gabriel Catano | Zendy; Thomas F. Patterson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris

Author(s) -

Nathan P. Wiederhold,

Shawn R. Lockhart,

Laura K. Najvar,

Elizabeth L. Berkow,

Rosie Jaramillo,

Marcos Olivo,

Edward P. Garvey,

Christopher M. Yates,

Robert J. Schotzinger,

Gabriel Catano,

Thomas F. Patterson

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02233-18

Subject(s) - candida auris , fluconazole , caspofungin , in vivo , biology , broth microdilution , voriconazole , pharmacology , microbiology and biotechnology , medicine , minimum inhibitory concentration , antibiotics , antifungal

Candida auris is an emerging pathogen associated with significant mortality and often multidrug resistance. VT-1598, a tetrazole-based fungal CYP51-specific inhibitor, was evaluatedin vitro andin vivo againstC. auris .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research